Related Experiment Video
Updated: May 16, 2026
10:05
Techniques of Sleeve Gastrectomy and Modified Roux-en-Y Gastric Bypass in Mice
Published on: March 20, 2017
11.7K
Can obesity medications replace metabolic and bariatric surgery? A comprehensive review
Tak Ying Louise Ko1, R V Cohen2, Carel W le Roux1,3
1https://ror.org/05m7pjf47Diabetes Complications Research Centre, University College Dublin, Ireland.
The Proceedings of the Nutrition Society
|April 21, 2026
Summary
Obesity medications offer a scalable, less invasive alternative to bariatric surgery, achieving comparable weight loss. However, surgery provides more durable results, and neither fully replaces the other; combination therapy is key for managing obesity.
Area of Science:
- Metabolic and Bariatric Surgery
- Pharmacotherapy
- Obesity Management
Background:
- Metabolic and bariatric surgery (MBS) is the established gold standard for significant, sustained weight loss in obesity.
- Advancements in anti-obesity pharmacotherapy are yielding weight loss outcomes approaching those of surgery.
Purpose of the Study:
- To critically compare contemporary anti-obesity pharmacotherapy with MBS.
- To evaluate their mechanisms, weight loss, durability, safety, and long-term disease control.
Main Methods:
- Systematic review and critical comparison of existing literature on obesity medications and bariatric surgery.
- Analysis of weight loss outcomes, durability, safety profiles, and disease management.
Main Results:
- MBS offers superior short- and long-term weight loss with durable results but is difficult to scale.
- Pharmacotherapy is scalable and increasingly effective but requires adherence and may lead to weight regain upon cessation.
- Current obesity medications cannot fully replicate MBS's multifactorial physiological impacts.
Conclusions:
- Pharmacotherapy is not yet a replacement for MBS, as patient response varies.
- Combining surgical and pharmacological approaches can enhance treatment efficacy for complex obesity.
- Obesity medications offer a less invasive, scalable option, broadening patient treatment choices.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:24Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...